208 related articles for article (PubMed ID: 32908002)
21. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
22. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
23. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
[No Abstract] [Full Text] [Related]
24. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
25. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
27. Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy.
Joo KI; Jeong Y; Hwang SM; Shin M; Lee J; Sharma G; Lee H; Im SH; Cha HJ
Biomaterials; 2020 Dec; 263():120380. PubMed ID: 32942128
[TBL] [Abstract][Full Text] [Related]
28. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.
Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
[TBL] [Abstract][Full Text] [Related]
29. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
30. IL-32γ potentiates tumor immunity in melanoma.
Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
[TBL] [Abstract][Full Text] [Related]
31. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
[TBL] [Abstract][Full Text] [Related]
32. Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.
Guo Z; Li Y; Zhang D; Ma J
Oncotarget; 2017 Oct; 8(52):89761-89774. PubMed ID: 29163786
[TBL] [Abstract][Full Text] [Related]
33. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
34. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.
Zhu N; Weng S; Wang J; Chen J; Yu L; Fang X; Yuan Y
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3021-3036. PubMed ID: 31617075
[TBL] [Abstract][Full Text] [Related]
35. Photothermal therapies to improve immune checkpoint blockade for cancer.
Balakrishnan PB; Sweeney EE; Ramanujam AS; Fernandes R
Int J Hyperthermia; 2020 Dec; 37(3):34-49. PubMed ID: 33426992
[TBL] [Abstract][Full Text] [Related]
36. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
[TBL] [Abstract][Full Text] [Related]
37. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
38. PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer.
Spangle JM; Dreijerink KM; Groner AC; Cheng H; Ohlson CE; Reyes J; Lin CY; Bradner J; Zhao JJ; Roberts TM; Brown M
Cell Rep; 2016 Jun; 15(12):2692-704. PubMed ID: 27292631
[TBL] [Abstract][Full Text] [Related]
39. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
40. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
